FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2067103053> ?p ?o ?g. }

• W2067103053 endingPage "1185" @default.
• W2067103053 startingPage "1181" @default.
• W2067103053 abstract "To evaluate the virological efficacy and safety of quadruple therapy with two nucleoside analogues and ritonavir (400 mg twice daily) plus indinavir (400 mg twice daily) combination in antiretroviral therapy-naive patients.An open-label, uncontrolled multicentre trial. Antiretroviral therapy-naive patients (n = 90) with high median baseline HIV RNA levels of 220,000 copies/ml (range, 36,000-2,943,000 copies/ml) and median CD4 cell count of 189 x 10(6)/l (range, 4-656 x 10(6)/l) were started on a twice daily regimen of either zidovudine/lamivudine (49%), stavudine/lamivudine (38%) or stavudine/didanosine (13%) plus ritonavir 400 mg twice daily and indinavir 400 mg twice daily combination therapy. CD4 cell counts and HIV RNA were determined at weeks 0, 4, 8, 12, 16, 20, and 24. Statistical analysis was performed on treatment as well as intent-to-treat, where missing values were accounted for as failure.In the intent-to-treat analysis at week 24, the proportion of patients with HIV RNA of < 500 copies/ml, and < 80 copies/ml was 86.7% and 71.1%, respectively. In the on-treatment analysis at week 24, 80.0% of patients had undetectable viral load in the ultrasensitive assay (< 80 copies/ml; n = 80). The quadruple therapy was well tolerated except for mild diarrhoea, initial nausea and increased triglyceride levels. Treatment was stopped in seven (7.7%) patients because of adverse events and three (3.3%) were lost to follow-up.Our preliminary data suggest that the protease inhibitor combination ritonavir/indinavir plus double nucleoside therapy appears to be effective and safe in short-term treatment (up to 24 weeks)." @default.
• W2067103053 created "2016-06-24" @default.
• W2067103053 creator A5000517630 @default.
• W2067103053 creator A5002633651 @default.
• W2067103053 creator A5018838051 @default.
• W2067103053 creator A5025348858 @default.
• W2067103053 creator A5029093470 @default.
• W2067103053 creator A5054617732 @default.
• W2067103053 creator A5062744631 @default.
• W2067103053 creator A5062778314 @default.
• W2067103053 creator A5078767364 @default.
• W2067103053 creator A5080153013 @default.
• W2067103053 creator A5080679517 @default.
• W2067103053 date "2000-06-01" @default.
• W2067103053 modified "2023-09-27" @default.
• W2067103053 title "Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals" @default.
• W2067103053 cites W1871950822 @default.
• W2067103053 cites W1980099829 @default.
• W2067103053 cites W1983223527 @default.
• W2067103053 cites W1990720570 @default.
• W2067103053 cites W2001471009 @default.
• W2067103053 cites W2008383946 @default.
• W2067103053 cites W2149335010 @default.
• W2067103053 cites W2329393410 @default.
• W2067103053 cites W2332060437 @default.
• W2067103053 cites W2339219218 @default.
• W2067103053 cites W2339827976 @default.
• W2067103053 doi "https://doi.org/10.1097/00002030-200006160-00015" @default.
• W2067103053 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10894282" @default.
• W2067103053 hasPublicationYear "2000" @default.
• W2067103053 type Work @default.
• W2067103053 sameAs 2067103053 @default.
• W2067103053 citedByCount "37" @default.
• W2067103053 countsByYear W20671030532015 @default.
• W2067103053 crossrefType "journal-article" @default.
• W2067103053 hasAuthorship W2067103053A5000517630 @default.
• W2067103053 hasAuthorship W2067103053A5002633651 @default.
• W2067103053 hasAuthorship W2067103053A5018838051 @default.
• W2067103053 hasAuthorship W2067103053A5025348858 @default.
• W2067103053 hasAuthorship W2067103053A5029093470 @default.
• W2067103053 hasAuthorship W2067103053A5054617732 @default.
• W2067103053 hasAuthorship W2067103053A5062744631 @default.
• W2067103053 hasAuthorship W2067103053A5062778314 @default.
• W2067103053 hasAuthorship W2067103053A5078767364 @default.
• W2067103053 hasAuthorship W2067103053A5080153013 @default.
• W2067103053 hasAuthorship W2067103053A5080679517 @default.
• W2067103053 hasBestOaLocation W20671030531 @default.
• W2067103053 hasConcept C126322002 @default.
• W2067103053 hasConcept C142462285 @default.
• W2067103053 hasConcept C159047783 @default.
• W2067103053 hasConcept C197934379 @default.
• W2067103053 hasConcept C2522874641 @default.
• W2067103053 hasConcept C2776999253 @default.
• W2067103053 hasConcept C2777210460 @default.
• W2067103053 hasConcept C2777447569 @default.
• W2067103053 hasConcept C2777869810 @default.
• W2067103053 hasConcept C2779298103 @default.
• W2067103053 hasConcept C2779889181 @default.
• W2067103053 hasConcept C2780216070 @default.
• W2067103053 hasConcept C2780593183 @default.
• W2067103053 hasConcept C2780727368 @default.
• W2067103053 hasConcept C2780866839 @default.
• W2067103053 hasConcept C2781413609 @default.
• W2067103053 hasConcept C2993143319 @default.
• W2067103053 hasConcept C71924100 @default.
• W2067103053 hasConcept C90924648 @default.
• W2067103053 hasConcept C98274493 @default.
• W2067103053 hasConceptScore W2067103053C126322002 @default.
• W2067103053 hasConceptScore W2067103053C142462285 @default.
• W2067103053 hasConceptScore W2067103053C159047783 @default.
• W2067103053 hasConceptScore W2067103053C197934379 @default.
• W2067103053 hasConceptScore W2067103053C2522874641 @default.
• W2067103053 hasConceptScore W2067103053C2776999253 @default.
• W2067103053 hasConceptScore W2067103053C2777210460 @default.
• W2067103053 hasConceptScore W2067103053C2777447569 @default.
• W2067103053 hasConceptScore W2067103053C2777869810 @default.
• W2067103053 hasConceptScore W2067103053C2779298103 @default.
• W2067103053 hasConceptScore W2067103053C2779889181 @default.
• W2067103053 hasConceptScore W2067103053C2780216070 @default.
• W2067103053 hasConceptScore W2067103053C2780593183 @default.
• W2067103053 hasConceptScore W2067103053C2780727368 @default.
• W2067103053 hasConceptScore W2067103053C2780866839 @default.
• W2067103053 hasConceptScore W2067103053C2781413609 @default.
• W2067103053 hasConceptScore W2067103053C2993143319 @default.
• W2067103053 hasConceptScore W2067103053C71924100 @default.
• W2067103053 hasConceptScore W2067103053C90924648 @default.
• W2067103053 hasConceptScore W2067103053C98274493 @default.
• W2067103053 hasIssue "9" @default.
• W2067103053 hasLocation W20671030531 @default.
• W2067103053 hasLocation W20671030532 @default.
• W2067103053 hasLocation W20671030533 @default.
• W2067103053 hasOpenAccess W2067103053 @default.
• W2067103053 hasPrimaryLocation W20671030531 @default.
• W2067103053 hasRelatedWork W1750049371 @default.
• W2067103053 hasRelatedWork W2039961216 @default.
• W2067103053 hasRelatedWork W2066184048 @default.
• W2067103053 hasRelatedWork W2067103053 @default.
• W2067103053 hasRelatedWork W2080401395 @default.

• next